Skip to Main Content

Paper Details

Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi.
JAMA Dermatol
8
2021
-ROS1 fusions, Crizotinib, GOPC, GOPC-, HRAS oncogene, Patient, ROS1, ROS1 protein, Spitz nevi, agminated Spitz nevi, benign, benign melanocytic neoplasms, crizotinib, facial agminated Spitz nevi, girl, nevus, nevus spilus, oncogenic gene, patient, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Ann-Marie PatchQIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute
Ann-Marie PatchQIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute
Nicholas K HaywardQIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute
Nicholas K HaywardQIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute
Richard A ScolyerMelanoma Institute Australia, University of Sydney
Richard A ScolyerRoyal Prince Alfred Hospital
Richard A ScolyerSydney Medical School, University of Sydney
Nicola WaddellQIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute
Nicola WaddellQIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute
  • 1 - 9

Datasets

Release 1.2